BGNE Stock Recent News

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., will report its first quarter 2025 financial results on Wednesday, May 7, 2025 before the financial markets open. Following the release of the financials, the Company will host a live webcast with management at 8:00 a.m. ET. The conference call will be webcast live and a link to the webcast can be accessed from the investo.

RBC Capital initiated coverage of BeiGene with an Outperform rating and $312 price target. RBC sees a path to robust revenue growth driven by Brukinsa's market dominance and high-value follow-on assets in the hematology-oncology space, the analyst tells investors in a research note. BeiGene's oncology pipeline, proven R&D capabilities, and a fast to-execution mindset are key ingredients for the company's emerging position as a global oncology powerhouse that could drive market capitalization expansion, the firm says.

BeiGene Ltd ONC on Thursday announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced the discontinuation of its clinical development program for ociperlimab (BGB-A1217), an anti-TIGIT antibody, as a potential treatment for lung cancer. The Independent Data Monitoring Committee recommended terminating the ongoing Phase 3 AdvanTIG-302 trial (NCT04746924) based on its findings as part of a pre.

SAN CARLOS, Calif.--(BUSINESS WIRE)---- $BGNE #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency issued a positive opinion recommending approval of TEVIMBRA® (tislelizumab), in combination with etoposide and platinum chemotherapy, as a first-line treatment for adult patients with extensive-stage small cell l.

On Tuesday, BeiGene Ltd ONC announced FDA approval for Tevimbra (tislelizumab-jsgr), in combination with platinum-containing chemotherapy, for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1).

BeiGene is a BUY due to Tevimbra's approval and Brukinsa's growing sales, leading to anticipated positive earnings in 2025. Q4 and full-year 2024 revenues surged to $1.1B and $3.8B respectively, with a 78% and 55% increase, positioning BeiGene for profitability. BeiGene announced a name change to BeOne Medicines, transitioning from historical losses to profitability, and potentially attracting new buyers.

While the top- and bottom-line numbers for BeiGene (ONC) give a sense of how the business performed in the quarter ended December 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

BeiGene, Ltd. (NASDAQ:ONC ) Q4 2024 Earnings Conference Call February 27, 2025 8:00 AM ET Company Participants Dan Maller - Head, Investor Relations John Oyler - Co-Founder, Chairman & Chief Executive Officer Matt Shaulis - General Manager, North America Lai Wang - Global Head, R&D Aaron Rosenberg - Chief Financial Officer Conference Call Participants Kelly Shi - Jefferies Sean Laaman - Morgan Stanley & Co. Andrew Berens - Leerink Partners Jessica Fye - JPMorgan Yigal Nochomovitz - Citigroup Reni Benjamin - Citizens JMP Ziyi Chen - Goldman Sachs & Co Operator Good day, everyone.

SAN MATEO, Calif.--(BUSINESS WIRE)---- $ONC #BeiGene--BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced financial results and corporate updates from the fourth quarter and full year 2024. “Our fourth quarter and full year results demonstrate our tremendous growth as a global oncology powerhouse, reinforced by the continued success of BRUKINSA and the development of one of the most prolific solid tumor pipeline.